Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016.
Haemophilus influenzae
antimicrobial susceptibility
invasive disease
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
29 06 2022
29 06 2022
Historique:
pubmed:
11
5
2022
medline:
2
7
2022
entrez:
10
5
2022
Statut:
ppublish
Résumé
Antibiotics are important for the treatment and prevention of invasive Haemophilus influenzae disease. Reduced susceptibility to clinically relevant drugs, except ampicillin, has been uncommon in the United States. Susceptibility of 700 invasive H. influenzae isolates, collected through population-based surveillance during 2016, was assessed for 15 antibiotics using broth microdilution, according to the CLSI guidelines; a subset of 104 isolates were also assessed for rifampin susceptibility using Etest. Genomes were sequenced to identify genes and mutations known to be associated with reduced susceptibility to clinically relevant drugs. A total of 508 (72.6%) had reduced susceptibility to at least one antibiotic and more than half of the isolates exhibited reduced susceptibility to only one (33.6%) or two (21.6%) antibiotic classes. All tested isolates were susceptible to rifampin, a chemoprophylaxis agent, and <1% (
Identifiants
pubmed: 35536039
doi: 10.1128/spectrum.02579-21
pmc: PMC9241922
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ampicillin
7C782967RD
beta-Lactamases
EC 3.5.2.6
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257921Références
Clin Infect Dis. 2011 Dec;53(12):1230-6
pubmed: 22080119
Bioinformatics. 2009 Jun 1;25(11):1422-3
pubmed: 19304878
Antimicrob Agents Chemother. 1997 Feb;41(2):292-7
pubmed: 9021182
Antimicrob Agents Chemother. 1976 Feb;9(2):327-33
pubmed: 1083711
J Antimicrob Chemother. 2003 Mar;51(3):523-30
pubmed: 12615852
Emerg Infect Dis. 2015 Sep;21(9):1520-8
pubmed: 26292067
Diagn Microbiol Infect Dis. 1997 Jul;28(3):105-12
pubmed: 9294699
J Clin Microbiol. 1991 Mar;29(3):533-8
pubmed: 2037671
BMC Genomics. 2019 Oct 12;20(1):733
pubmed: 31606037
Int J Med Microbiol. 2011 Apr;301(4):303-9
pubmed: 21276750
Lancet. 1975 Mar 29;1(7909):716-9
pubmed: 47483
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391
Am J Med. 1995 Dec 29;99(6B):3S-7S
pubmed: 8585554
Clin Infect Dis. 2001 May 15;32 Suppl 2:S81-93
pubmed: 11320449
Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9
pubmed: 11353613
Antimicrob Agents Chemother. 2007 Jul;51(7):2564-73
pubmed: 17470649
Clin Infect Dis. 2002 Mar 1;34 Suppl 1:S4-S16
pubmed: 11810606
Clin Microbiol Infect. 2017 Feb;23(2):118.e9-118.e19
pubmed: 27756711
Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2201-2210
pubmed: 30145620
Antimicrob Agents Chemother. 2005 Jun;49(6):2561-4
pubmed: 15917574
PLoS One. 2016 Feb 01;11(2):e0147765
pubmed: 26829233
Antimicrob Agents Chemother. 2002 Feb;46(2):550-5
pubmed: 11796376
J Antimicrob Chemother. 2020 Aug 1;75(8):2076-2086
pubmed: 32449913
Diagn Microbiol Infect Dis. 2014 Apr;78(4):443-8
pubmed: 24492025
J Clin Microbiol. 1991 Jan;29(1):109-14
pubmed: 1993744
J Clin Microbiol. 2003 Jan;41(1):393-6
pubmed: 12517878
Antimicrob Agents Chemother. 2007 Sep;51(9):3155-61
pubmed: 17620383
Diagn Microbiol Infect Dis. 1997 Dec;29(4):249-57
pubmed: 9458982
Euro Surveill. 2014 Dec 11;19(49):
pubmed: 25523969
Antimicrob Agents Chemother. 2002 Jul;46(7):2208-18
pubmed: 12069976
Clin Infect Dis. 2018 Aug 31;67(6):881-889
pubmed: 29509834
Antimicrob Agents Chemother. 2007 Nov;51(11):3969-76
pubmed: 17698631
Lancet. 1981 Nov 7;2(8254):1008-10
pubmed: 6118476
Clin Microbiol Rev. 2007 Apr;20(2):368-89
pubmed: 17428889